Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
51.72
Nov 19 • 11:53 AM ET Dollar change+0.75 Percentage change(1.47%)
Index
-
Market Cap
31.89B
Enterprise Value
35.23B
Income
728.39M
Sales
4.30B
Book/sh
10.30
Cash/sh
3.02
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
3029
IPO
Jun 01, 2009
P/E
44.31
Forward P/E
31.95
PEG
1.57
P/S
7.42
P/B
5.02
P/C
17.15
P/FCF
37.46
EV/EBITDA
24.83
EV/Sales
8.20
Quick Ratio
2.43
Current Ratio
2.45
Debt/Eq
0.82
LT Debt/Eq
0.77
Option/Short
Yes / Yes
EPS (ttm)
1.17
EPS next Y
1.62
EPS next Q
0.21
EPS this Y
-18.29%
EPS next Y
28.90%
EPS next 5Y
20.35%
EPS past 3/5Y
9.68% 6.84%
Sales past 3/5Y
22.11% 19.27%
EPS Y/Y TTM
-50.40%
Sales Y/Y TTM
19.61%
EPS Q/Q
-14.87%
Sales Q/Q
16.55%
Insider Own
1.75%
Insider Trans
0.00%
Inst Own
20.04%
Inst Trans
0.18%
ROA
7.30%
ROE
12.06%
ROIC
6.51%
Gross Margin
92.60%
Oper. Margin
30.63%
Profit Margin
16.96%
SMA20
-1.39%
SMA50
21.32%
SMA200
62.05%
Trades
Shs Outstand
614.95M
Shs Float
605.81M
52W High
59.97 -13.76%
52W Low
23.62 118.97%
Volatility
2.48% 5.29%
ATR (14)
2.07
RSI (14)
58.87
Beta
0.74
Rel Volume
1.49
Avg Volume
4.19M
Volume
2,487,973
Perf Week
-0.04%
Perf Month
30.71%
Perf Quarter
54.62%
Perf Half Y
91.20%
Perf YTD
67.92%
Perf Year
69.19%
Perf 3Y
57.68%
Perf 5Y
24.72%
Perf 10Y
191.38%
Prev Close
50.97
Price
51.72
Change %
1.47%
Consensus
Buy
Avg. Price Target
$64.44
Implied Upside
+24.6%
Analysts18incl. previous ratings
Rating Distribution15 Buy · 1 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 27, 2026Upgrade
JPM logoJJP Morgan
Neutral → Overweight
Jul 22, 2026Upgrade
TD logoTTD Cowen
Hold → Buy$43-16.9%
May 27, 2026Initiated
TFC logoTTruist
Buy$40-22.7%
Apr 22, 2026Upgrade
GS logoGGoldman
Neutral → Buy
Mar 27, 2026Initiated
WWolfe Research
Outperform$32-38.1%
Mar 02, 2026Initiated
WFC logoWWells Fargo
Overweight$40-22.7%
Feb 17, 2026Resumed
MS logoMMorgan Stanley
Equal-Weight$34-34.3%
Feb 17, 2026Resumed
JEF logoJJefferies
Buy$41.50-19.8%
Sep 23, 2025Upgrade
GGuggenheim
Neutral → Buy$43-16.9%
Apr 01, 2025Downgrade
BBernstein
Mkt Perform → Underperform
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klimovsky Judith V.OfficerNov 10 '26Proposed Sale556.781,265704,327Nov 10 12:45 PM
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Co-FounderDr. Jan G.J. van de Winkel Ph.D.
Executive VP & CFOMr. Anthony Pagano CPA
Executive VP & Chief Technical Operations OfficerMr. Rayne Waller
Executive VPMr. Gregory David Emil Mueller
Executive VP & Chief People OfficerMr. Christopher Cozic